Search

Your search keyword '"van Rijn, R.S."' showing total 27 results
Start Over Author "van Rijn, R.S."
27 results on '"van Rijn, R.S."'

1. Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry

Author

Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Bloem, M., Blokx, W.A.M., Boers-Sonderen, M.J., Bonenkamp, J.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Haanen, J.B., Holtslag, C.E., Hospers, G.A.P., Piersma, D., van Rijn, R.S., Stevense-den Boer, A.M., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Vreugdenhil, G., Wouters, M.W.J.M., Portielje, J.E.A., and de Glas, N.A.

Published
2024
Full Text
View/download PDF

2. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Author

Geurts, Y.M., Neppelenbroek, S.I.M., Aleman, B.M.P., Janus, C.P.M., Krol, A.D.G., van Spronsen, D.J., Plattel, W.J., Roesink, J.M., Verschueren, K.M.S., Zijlstra, J.M., Koene, H.R., Nijziel, M.R., Schimmel, E.C., de Jongh, E., Ong, F., te Boome, L.C.J., van Rijn, R.S., Böhmer, L.H., Ta, B.D.P., Visser, H.P.J., Posthuma, E.F.M., Bilgin, Y.M., Muller, K., van Kampen, D., So-Osman, C., Vermaat, J.S.P., de Weijer, R.J., Kersten, M.J., van Leeuwen, F.E., and Schaapveld, M.

Published
2024
Full Text
View/download PDF

3. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

Author

Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., and Uyl-de Groot, C.A.

Published
2021
Full Text
View/download PDF

4. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma

Author

van Duin, I.A.J., primary, Elias, S.G., additional, Van Den Eertwegh, F., additional, de Groot, J.W.B., additional, Blokx, W.A.M., additional, van Not, O.J., additional, Aarts, M., additional, Blank, C.U., additional, Haanen, J.B.A.G., additional, Hospers, G., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, and Suijkerbuijk, K.P.M., additional

Published
2022
Full Text
View/download PDF

5. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma

Author

van Not, O.J., primary, Van Den Eertwegh, F., additional, Haanen, J.B.A.G., additional, van Rijn, R.S., additional, Aarts, M., additional, Van den Berkmortel, F., additional, Blank, C.U., additional, Boers-Sonderen, M., additional, de Groot, J.W.B., additional, Hospers, G., additional, Kapiteijn, E., additional, De Meza, M.M., additional, Piersma, D., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Blokx, W.A.M., additional, and Suijkerbuijk, K.P.M., additional

Published
2022
Full Text
View/download PDF

6. Survival of stage IV melanoma in Belgium and the Netherlands

Author

Suijkerbuijk, K.P.M., primary, Haanen, J.B.A.G., additional, Boers‐Sonderen, M.J., additional, Hospers, G.A.P., additional, Blank, C.U., additional, van den Berkmortel, F.W.P.J., additional, de Groot, J.W.B., additional, Piersma, D., additional, Aarts, M.J.B., additional, van Rijn, R.S., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Kapiteijn, E., additional, van der Veldt, A.A.M., additional, and van den Eertwegh, A.J.M., additional

Published
2021
Full Text
View/download PDF

7. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands

Author

Breeschoten, J.V., primary, Van den Eertwegh, A.J.M., additional, de Wreede, L., additional, Hilarius, D., additional, van Zwet, E., additional, Haanen, J.B.A.G., additional, Blank, C.U., additional, Aarts, M., additional, Van den Berkmortel, F., additional, de Groot, J.W.B., additional, Hospers, G.A., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Boers-Sonderen, M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional

Published
2021
Full Text
View/download PDF

8. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality

Author

De Meza, M.M., primary, Ismail, R., additional, Blokx, W.A.M., additional, Blank, C.U., additional, Van den Eertwegh, A.J.M., additional, Aarts, M., additional, van Akkooi, A.C.J., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, de Groot, J.W.B., additional, Haanen, J.B.A.G., additional, Hospers, G.A., additional, Piersma, D., additional, van Rijn, R.S., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional

Published
2021
Full Text
View/download PDF

9. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, J. (Jesper), Wouters, M.W.J.M. (Michel W. J. M.), Hilarius, D.L. (Doranne L.), Haanen, J.B. (John), Blank, C.U. (Christian U.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Roos S.), Suijkerbuijk, K.P.M. (Karin), Blokx, W.A.M. (W. A M), Tije, B.-J.J. (Bert-Jan J. ten), Veldt, A.A.M. (Astrid A. M. van der), Vreugdenhil, A. (Art), Boers-Sonderen, M.J. (M.), van den Eertwegh, A.J.M. (Alfonsus J. M.), van Breeschoten, J. (Jesper), Wouters, M.W.J.M. (Michel W. J. M.), Hilarius, D.L. (Doranne L.), Haanen, J.B. (John), Blank, C.U. (Christian U.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Roos S.), Suijkerbuijk, K.P.M. (Karin), Blokx, W.A.M. (W. A M), Tije, B.-J.J. (Bert-Jan J. ten), Veldt, A.A.M. (Astrid A. M. van der), Vreugdenhil, A. (Art), Boers-Sonderen, M.J. (M.), and van den Eertwegh, A.J.M. (Alfonsus J. M.)

Abstract

Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients. Methods: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. Results: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7–24.3) and 85.4% (95% CI: 58.1–73.6) vs. 41.7% (95% CI: 34.2–51.0). Conclusions: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.

Published
2021
Full Text
View/download PDF

10. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, R.K. (Rawa K.), Sikkes, N.O. (Nienke O.), Wouters, M.W.J.M. (Michel W J M), Hilarius, D.L. (Doranne L.), Pasmooij, A.M.G. (Anna M G), van den Eertwegh, A.J.M. (Alfonsus J M), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Roos S.), Suijkerbuijk, K.P.M. (Karin), Ten Tije, B.-J. (Bert-Jan), Veldt, A.A.M. (Astrid) van der, Vreugdenhil, A. (Art), van Dartel, M. (Maaike), de Boer, A. (Anthonius), Ismail, R.K. (Rawa K.), Sikkes, N.O. (Nienke O.), Wouters, M.W.J.M. (Michel W J M), Hilarius, D.L. (Doranne L.), Pasmooij, A.M.G. (Anna M G), van den Eertwegh, A.J.M. (Alfonsus J M), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Roos S.), Suijkerbuijk, K.P.M. (Karin), Ten Tije, B.-J. (Bert-Jan), Veldt, A.A.M. (Astrid) van der, Vreugdenhil, A. (Art), van Dartel, M. (Maaike), and de Boer, A. (Anthonius)

Abstract

Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to investigate whether a patient registry can complement or even replace postapproval trials. Postapproval single-arm clinical trial data from the Medicines Evaluation Board and real-world data from the Dutch Melanoma Treatment Registry were used. The study population consisted of advanced melanoma patients with brain metastases treated with targeted therapies (BRAF- or BRAF-MEK inhibitors) in the first line. A Cox hazard regression model and a propensity score matching (PSM) model were used to compare the two patient populations. Compared to patients treated in postapproval trials (n = 467), real-world patients (n = 602) had significantly higher age, higher ECOG performance status, more often ≥3 organ involvement and more symptomatic brain metastases. Lactate dehydrogenase levels were similar between both groups. The unadjusted median overall survival (mOS) in postapproval clinical trial patients was 8.7 (95% CI, 8.1-10.4) months compared to 7.2 (95% CI, 6.5-7.7) months (P < 0.01) in real-world patients. With the Cox hazard regression model, survival was adjusted for prognostic factors, which led to a statistically insignificant difference in mOS for trial and real-world patients of 8.7 (95% CI, 7.9-10.4) months compared to 7.3 (95% CI, 6.3-7.9) months, respectively. The PSM model resulted in 310 matched patients with similar survival (P = 0.9). Clinical outcomes of both data sources were similar. Registries could be a compleme

Published
2021
Full Text
View/download PDF

12. Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy

Author

Blankenstein, S.A. (Stephanie A.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Eertwegh, A.J.M. (Fons) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), Van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Van Der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), Akkooi, A.C.J. (Alexander) van, Blankenstein, S.A. (Stephanie A.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Eertwegh, A.J.M. (Fons) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), Van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Van Der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), and Akkooi, A.C.J. (Alexander) van

Abstract

Opportunities for surgical treatment in metastatic melanoma patients have re-emerged due to the development of novel systemic therapeutics over the past decade. The aim of this study is to present data on outcomes of surgery in patients with unresectable stage IIIC and IV melanoma, who have previously been treated with immunotherapy or targeted therapy. Data was extracted from the Dutch Melanoma Treatment Registry (DMTR) on 154 patients obtaining disease control to systemic therapy and undergoing subsequent surgery. Disease control was defined as a complete response (CR), which was seen in 3.2% of patients; a partial response (PR), seen in 46.1% of patients; or stable disease (SD), seen in 44.2% of patients. At a median follow-up of 10.0 months (interquartile range 4-22) after surgery, the median overall survival (OS) had not been reached in our cohort and median progression-free survival (PFS) was 9.0 months (95% CI 6.3-11.7). A CR or PR at first follow-up after surgery was associated with both a better OS and PFS compared to stable or progressive disease (p < 0.001). We conclude that selected patients can benefit from surgery after achieving disease control with systemic therapy.

Published
2020
Full Text
View/download PDF

13. Real-world outcomes of advanced melanoma patients not represented in phase III trials

Author

van Zeijl, M.C.T. (Michiel C. T.), Ismail, R.K. (Rawa K.), de Wreede, L.C. (Liesbeth C.), van den Eertwegh, A.J.M. (Alfonsus J. M.), De Boer, A. (Anthonius), van Dartel, M. (Maaike), Hilarius, D.L. (Doranne L.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, van der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Haanen, J.B.A.G. (John B. A. G.), Wouters, M.W.J.M. (Michel), van Zeijl, M.C.T. (Michiel C. T.), Ismail, R.K. (Rawa K.), de Wreede, L.C. (Liesbeth C.), van den Eertwegh, A.J.M. (Alfonsus J. M.), De Boer, A. (Anthonius), van Dartel, M. (Maaike), Hilarius, D.L. (Doranne L.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, van der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Haanen, J.B.A.G. (John B. A. G.), and Wouters, M.W.J.M. (Michel)

Abstract

The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision-making. Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met ≥1 trial exclusion criteria. These criteria were derived from the KEYNOTE-006 and CHECKMATE-067/-066 phase III trials. Prognostic importance of factors associated with overall survival (OS) was assessed with the Kaplan-Meier method, Cox models, predicted OS probabilities of prognostic subgroups and a conditional inference survival tree (CIST). A nationwide population-based registry was used as data source. Of 2536 systemically treated patients with advanced melanoma, 1004 (40%) patients were ineligible for phase IIII trials. Ineligible patients had a poorer median OS (mOS) compared to eligible patients (8.8 vs 23 months). Eligibility criteria strongly associated with OS in systemically treated ineligible patients were Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≥2, brain metastases (BM) and lactate dehydrogenase (LDH) of >500 U/L. Patients with ECOG PS of ≥2 with or without symptomatic BM had a predicted mOS of 6.5 and 11.3 months and a 3-year survival probability of 9.3% and 23.6%, respectively. The CIST showed the strongest prognostic covariate for survival was LDH, followed by ECOG PS. The prognosis of patients with LDH of >500 U/L is poor, but long-term survival is possible. The prognosis of ineligible patients with advanced melanoma in real-world was very heterogeneous and highly dependent on LDH value, ECOG PS and symptomatic BM.

Published
2020
Full Text
View/download PDF

14. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

Author

van Zeijl, M.C.T., primary, de Wreede, L.C., additional, van den Eertwegh, A.J.M., additional, Wouters, M.W.J.M., additional, Jochems, A., additional, Schouwenburg, M.G., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, de Groot, J.W.B., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, van der Hoeven, J.J.M., additional, and Haanen, J.B.A.G., additional

Published
2021
Full Text
View/download PDF

15. Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry

Author

Jochems, A. (Anouk), van der Kooij, M.K. (Monique K.), Fiocco, M. (Marta), Schouwenburg, M.G., Aarts, M.J. (Mieke), Akkooi, A.C.J. (Alexander) van, Berkmortel, F.W.P.J. (Franchette) van den, Blank, C.U. (Christian U.), van den Eertwegh, A.J.M. (Alfonsus J. M.), Franken, M.G. (Margreet), de Groot, J.B. (Janwillem B.), Haanen, J.B. (John), Hospers, G.A.P. (Geke), Koornstra, R.H.T. (Rutger), Kruit, W.H.J. (Wim), Louwman, M.W.J. (Marieke), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), van Zeijl, M.C.T. (Michiel C. T.), van der Hoeven, K.J.M. (Koos J. M.), Kapiteijn, E. (Ellen), Jochems, A. (Anouk), van der Kooij, M.K. (Monique K.), Fiocco, M. (Marta), Schouwenburg, M.G., Aarts, M.J. (Mieke), Akkooi, A.C.J. (Alexander) van, Berkmortel, F.W.P.J. (Franchette) van den, Blank, C.U. (Christian U.), van den Eertwegh, A.J.M. (Alfonsus J. M.), Franken, M.G. (Margreet), de Groot, J.B. (Janwillem B.), Haanen, J.B. (John), Hospers, G.A.P. (Geke), Koornstra, R.H.T. (Rutger), Kruit, W.H.J. (Wim), Louwman, M.W.J. (Marieke), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), van Zeijl, M.C.T. (Michiel C. T.), van der Hoeven, K.J.M. (Koos J. M.), and Kapiteijn, E. (Ellen)

Abstract

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survi

Published
2019
Full Text
View/download PDF

16. PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?

Author

Franken, M.G., primary, Leeneman, B., additional, Van Zeijl, M., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, van den Eertwegh, A.J.M., additional, de Groot, J.W.B., additional, Herbschleb, K.H., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M.W.J.M., additional, Haanen, J.B.A.G., additional, and Uyl-de Groot, C., additional

Published
2019
Full Text
View/download PDF

17. PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

Author

Leeneman, B., primary, Franken, M.G., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, van den Eertwegh, A.J.M., additional, de Groot, J.W.B., additional, Herbschleb, K.H., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M.W.J.M., additional, Haanen, J.B.A.G., additional, and Uyl-de Groot, C., additional

Published
2019
Full Text
View/download PDF

18. Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands

Author

van Zeijl, M.C.T., primary, Wouters, M W J M, additional, van den Eertwegh, A.J.M., additional, de Wreede, L.C., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, Van den Berkmortel, F W P J, additional, de Groot, J.W., additional, Boers-Sonderen, M.J., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, Ten Tije, A.J., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, and Haanen, J B A G, additional

Published
2019
Full Text
View/download PDF

20. Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population

Author

van Zeijl, M.C.T. (M. C.T.), Wouters, M.W.J.M. (Michel), Eertwegh, A.J.M. (Fons) van den, Aarts, M.J. (Mieke), Akkooi, A.C.J. (Alexander) van, Berkmortel, F.W.P.J. (Franchette) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Herbschleb, K.H. (K. H.), Hoeven, J. (John) van der, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (R. S.), Suijkerbuijk, K.P.M. (K. P.M.), Tije, A.J. (Albert Jan) ten, Van der Veldt, A.A.M. (A. A.M.), Vreugdenhil, G. (Gerard), Haanen, J.B. (John), van Zeijl, M.C.T. (M. C.T.), Wouters, M.W.J.M. (Michel), Eertwegh, A.J.M. (Fons) van den, Aarts, M.J. (Mieke), Akkooi, A.C.J. (Alexander) van, Berkmortel, F.W.P.J. (Franchette) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Herbschleb, K.H. (K. H.), Hoeven, J. (John) van der, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (R. S.), Suijkerbuijk, K.P.M. (K. P.M.), Tije, A.J. (Albert Jan) ten, Van der Veldt, A.A.M. (A. A.M.), Vreugdenhil, G. (Gerard), and Haanen, J.B. (John)

Published
2018
Full Text
View/download PDF

21. PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

Author

Leeneman, B., primary, Franken, M., additional, Aarts, M.J., additional, van Akkooi, A.C., additional, van den Berkmortel, F.W., additional, van den Eertwegh, A.J., additional, de Groot, J.W., additional, Herbschleb, K.H., additional, van der Hoeven, K.J., additional, Hospers, G.A., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P., additional, ten Tije, A.J., additional, van der Veldt, A.A., additional, Vreugdenhil, G., additional, Wouters, M.W., additional, van Zeijl, M.C., additional, Haanen, J.B., additional, and Uyl-de Groot, C.A., additional

Published
2018
Full Text
View/download PDF

22. Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population

Author

van Zeijl, M.C.T., primary, Wouters, M.W.J.M., additional, van den Eertwegh, A.J., additional, Aarts, M.J., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, Franken, M.G., additional, de Groot, J.W.B., additional, Herbschleb, K.H., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, Ten Tije, A.J., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, and Haanen, J.B.A.G., additional

Published
2018
Full Text
View/download PDF

23. 1353P - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands

Author

van Zeijl, M.C.T., Wouters, M W J M, van den Eertwegh, A.J.M., de Wreede, L.C., Aarts, M.J.B., van Akkooi, A.C.J., Van den Berkmortel, F W P J, de Groot, J.W., Boers-Sonderen, M.J., van der Hoeven, J.J.M., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., Ten Tije, A.J., Van der Veldt, A.A.M., Vreugdenhil, G., and Haanen, J B A G

Published
2019
Full Text
View/download PDF

24. 1276P - Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population

Author

van Zeijl, M.C.T., Wouters, M.W.J.M., van den Eertwegh, A.J., Aarts, M.J., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Franken, M.G., de Groot, J.W.B., Herbschleb, K.H., van der Hoeven, J.J.M., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., Ten Tije, A.J., Van der Veldt, A.A.M., Vreugdenhil, G., and Haanen, J.B.A.G.

Published
2018
Full Text
View/download PDF

26. Survival of stage IV melanoma in Belgium and the Netherlands.

Author

Suijkerbuijk, K.P.M., Haanen, J.B.A.G., Boers‐Sonderen, M.J., Hospers, G.A.P., Blank, C.U., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Piersma, D., Aarts, M.J.B., van Rijn, R.S., Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., van der Veldt, A.A.M., and van den Eertwegh, A.J.M.

Subjects
MELANOMA, RESEARCH grants, TRAVEL costs
Abstract

Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche. [Extracted from the article]

Published
2022
Full Text
View/download PDF

27. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.

Author

Advanced drug delivery systems/drug targeting, Dep Farmaceutische wetenschappen, Mutis, T., van Rijn, R.S., Simonetti, E.R., Aarts-Riemens, T., Emmelot, M.E., van Bloois, L., Martens, A.C.M., Verdonck, L.F., Ebeling, S.B., Advanced drug delivery systems/drug targeting, Dep Farmaceutische wetenschappen, Mutis, T., van Rijn, R.S., Simonetti, E.R., Aarts-Riemens, T., Emmelot, M.E., van Bloois, L., Martens, A.C.M., Verdonck, L.F., and Ebeling, S.B.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results